Elahere (mirvetuximab soravtansine-gynx) is a prescription medication designed for the treatment of adult patients with folate receptor-alpha (FRa) positive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. It is specifically indicated for individuals who have not responded to or are no longer responding to platinum-based chemotherapy and have received one to three prior types of chemotherapy. Elahere functions as an antibody-drug conjugate (ADC), delivering a cytotoxic agent directly to FRa-positive cancer cells, thereby minimizing damage to healthy tissues.
The elahere market consists of sales, by entities (organizations, sole traders or partnerships), of elahere (mirvetuximab soravtansine-gynx), a targeted antibody-drug conjugate (ADC) specifically designed for treating platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers that express high levels of folate receptor-alpha (FRa).
The global elahere market accounted to $502.56 million in 2024. The growth in the historic period can be attributed to technological advancements and increase in demand for personalized medicine.
Rising Healthcare Expenditure
The rising healthcare expenditure supported the expansion of the elahere market during this historic period. Healthcare expenditure refers to spending on healthcare costs and represents the total amount of money spent on healthcare-related goods and services within a given healthcare system or economy. Increased financial resources in the healthcare sector enable greater investment in innovative treatments, research and development. This funding helps cover the high costs associated with clinical trials, regulatory approvals and the scaling of production for cutting-edge therapies like Elahere. For instance, in 2023, according to the Canadian Institute for Health Information, a US-based not-for-profit organization, Canada's total health spending was estimated to reach $344 billion, or $8,740 per person. The growth in physician spending was estimated to be 6.9% in 2023 and 9.5% in 2022. Therefore, rising healthcare expenditure drove the growth of the elahere market.
Abbvie Secures European Approval For Elahere In Platinum-Resistant Ovarian Cancer
Companies in the elahere market are focusing on obtaining regulatory approvals to expand the treatment's availability for patients with platinum-resistant ovarian cancer. This move aims to strengthen its position in the market by offering a targeted therapy for a specific patient group in need of advanced treatment options. For instance, in November 2024, AbbVie, a US-based biotech company received approval from the European Commission for elahere as a treatment for adult patients with folate receptor-alpha (FR alpha) positive, platinum-resistant ovarian cancer. The approval was based on the positive results from the Phase III MIRASOL trial, which demonstrated a 35% reduction in the risk of disease progression or death compared to standard chemotherapy.
The global elahere market is highly concentrated, with only one player in the market. The top competitor in the market made up 100.0% of the total market in 2023.
Elahere Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global elahere market as it emerges from the COVID-19 shut down.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market research findings.
Benchmark performance against key competitors.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Where is the largest and fastest-growing market for elahere? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The elahere market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider elahere market; and compares it with other markets.
The report covers the following chapters
Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by clinical indication, by distribution channel and by end-users.
Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
Growth Analysis And Strategic Analysis Framework Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
Regional And Country Analysis- Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by clinical indication, by distribution channel and by end-users in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
Regional Market Size and Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
Conclusions And Recommendations- This section includes recommendations for elahere providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.